



Draft programme

Online Info session

Safety of cannabidiol as a novel food: data gaps and uncertainties |

28 June 2022

14:30-15:00 30'	Connection of participants to the platform	
15:00-15:10 10'	Welcome and introduction - chair	Ana Afonso (EFSA)
15:10-16:25 75'	Status of the safety assessment of CBD as Novel food Scope of the Panel's statement <ul style="list-style-type: none"> • ADME, CBD interaction with drug metabolism and gastrointestinal tract adverse effects (Q&A) • Liver (Q&A) • Neurological, psychiatric and psychologic effects (Q&A) • Endocrine and Reprotox (Q&A) • Presence of small particles, including nanoparticles, or production of CBD as nanomaterial and CBD nano-formulation (Q&A) 	Annamaria Rossi (EFSA) Harry McArdle (NDA WG Novel Food) Inge Mangelsdorf Karen-Ildico Hirsch-Ernst Jose Vicente Tarazona (EFSA)
16:25-16:40 15'	Experiences from suitability check and web-queries on CBD applications (Q&A)	Catalina Manieu (EFSA)
16:40-16:55	Q&A	Chair WG/Panel
16:55-17:00 5'	Concluding remarks & take-home messages	Chair